Drug Dosage for One Lung Cancer Treatment Calculated

Researchers in the United States, performed a budget impact analysis to compare fixed dosing of pembrolizumab dose with personalized.

A standard pembrolizumab dose (200mg) may be higher for treating metastatic non-small cell lung cancer effectively, as the dosage varies depending on the weight of the individual, reveals a new study .//

In October 2016, pembrolizumab became the new standard of care for firstline treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death ligand 1 in at least 50% of cells.

Pembrolizumab in Triple Negative Metastatic Breast Cancer
Pembrolizumab has shown some benefit in the treatment of triple negative metastatic breast cancer.

‘Pembrolizumab used in cancer immunotherapy, blocks a protective mechanism on cancer cells and allows the immune system to destroy these cells.’

The study was published in the Journal of the National Cancer Institute.

The standard dosage for pembrolizumab was based the KEYNOTE 024 trial. The dosage used in the trial was 200 mg for all patients (fixed dosing) every three weeks. As a result, this was the dose recommended by the Food and Drug Administration.

Multiple studies have demonstrated equivalent efficacy with lower weight-based doses (personalized dosing), however.

Multiple Cancers can be Treated With Pembrolizumab Combination Therapies
Adding pembrolizumab to standard therapies for breast cancer improved the number of patients achieving a pathological complete response.

The objective of this study was to compare the economic impact of using personalized dosing (2 mg/kg) vs fixed dosing (200 mg).

Researchers suspected that using the FDA-approved dose of 200 mg for all patients may be an unnecessarily high dose, given that the average weight in the United States is 82 kg.

Pembrolizumab - New Immunotherapy Drug For Mucosal Melanoma and Bladder Cancer
A new immunotherapy drug pembrolizumab is found to be active against mucosal melanoma and is found to prolong the lifespan of bladder cancer patients.

In an era of value-based cancer care, avoidance of drug wastage is of paramount importance. If dosed at 2 mg/kg, an appropriate dose for the average American adult would be 164 mg.

Researchers performed a budget impact analysis to compare fixed dosing with personalized. They calculated the target population and weight of patients who would be treated with pembrolizumab annually.

Pembrolizumab Approval Provides Noticeable Potential for Cancer Immunotherapy
Pembrolizumab drug approval for head and neck carcinoma is an advancement for the treatment of the disease as it scratches possible potential of immunotherapy.

Using survival curves they estimated the mean number of cycles that patients would receive. Using the Medicare average sales price, researchers calculated the difference in cost between personalized and fixed dosing.

The results of the study indicated that the total annual cost of pembrolizumab with fixed dosing is $3.4 billion, but with personalized dosing it would be $2.6 billion. The use of personalized dosing would likely lead to a 24.0% annual savings, some $825 million.

Using dosing manipulations such as that described for pembrolizumab could be one way for payers to improve value within the current system.

Although some cancer drug prices have increased in recent years, the price of pembrolizumab has remained fairly constant every quarter for the past six quarters at around $46 per mg.

Source-Eurekalert